Prophylaxis and treatment of COVID-19 related venous thromboembolism

References

• WorldHealthOrganization. Coronavirus disease (COVID-19) pandemic. Numbers at a glance. [cited 2020 Nov 26]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
   Google Scholar
• Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
   PubMed Web of Science ®Google Scholar
• Levi M, Thachil J, Iba T, et al. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020 Jun 01;7(6):e438–e440.
   PubMed Web of Science ®Google Scholar
• Cannegieter SC, Klok FA. COVID-19 associated coagulopathy and thromboembolic disease: commentary on an interim expert guidance. Res Pract Thromb Haemost. 2020 May;4(4):439–445.
   PubMed Web of Science ®Google Scholar
• Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020 Jul;191:9–14.
   PubMed Web of Science ®Google Scholar
• Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation. 2020 Jul 14;142(2):184–186.
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020 Jul;191:145–147.
   PubMed Web of Science ®Google Scholar
• Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020 Jun;46(6):1089–1098.
   PubMed Web of Science ®Google Scholar
• Nopp S, Moik F, Jilma B, et al. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost. 2020;4(7):1178–1191.
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020 Aug;18(8):1859–1865.
   PubMed Web of Science ®Google Scholar
• Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–1026.
   PubMed Web of Science ®Google Scholar
• Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest. 2020 Sep;158(3):1143–1163.
   PubMed Web of Science ®Google Scholar
• Bai C, Chotirmall SH, Rello J, et al. Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated international task force (29 July 2020). Eur Respir Rev. 2020;29(157):200287.
   PubMed Web of Science ®Google Scholar
• Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021;5(3):872–888.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19. Cited 2020 Nov 20. Available at: https://www.nice.org.uk/guidance/ng186
   Google Scholar
• National Institute of Health. Antithrombotic therapy in patients with COVID-19. Cited 2020 Dec 3. Available at: https://www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. N Engl J Med. 2020 Jul 9;383(2):120–128.
   PubMed Web of Science ®Google Scholar
• Ren B, Yan F, Deng Z, et al. Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan. Circulation. 2020 Jul 14;142(2):181–183.
   PubMed Web of Science ®Google Scholar
• van Dam LF, Kroft LJ, Dronkers CE, et al. Magnetic resonance direct thrombus imaging (MRDTI) can distinguish between old and new thrombosis in the abdominal aorta: a case report. Eur J Case Rep Intern Med. 2020;7(1):001351.
   PubMedGoogle Scholar
• van Dam LF, Kroft LJM, van der Wal LI, et al. Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? Thromb Res. 2020 Sep;193:86–89.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Bertinato EM, Birocchi S, et al. Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Thromb Haemost. 2020 Aug;120(8):1230–1232.
   PubMed Web of Science ®Google Scholar
• Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020 Jul;18(7):1743–1746.
   PubMed Web of Science ®Google Scholar
• Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020 Jun;18(6):1421–1424.
   PubMed Web of Science ®Google Scholar
• Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020 Jul;191:148–150.
   PubMed Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Valerio L, Ferrazzi P, Sacco C, et al. Course of D-Dimer and C-Reactive protein levels in survivors and nonsurvivors with COVID-19 Pneumonia: a retrospective analysis of 577 patients. Thromb Haemost. 2021 Jan;121(1):98–101.
   PubMedGoogle Scholar
• Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020;18(6):1324–1329.
   PubMed Web of Science ®Google Scholar
• Vidali S, Morosetti D, Cossu E, et al. D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review. ERJ Open Res. 2020;6(2):00260–2020.
   PubMedGoogle Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Li J, Liu Z, Wu G, et al. D-Dimer as a prognostic indicator in critically ill patients hospitalized with COVID-19 in Leishenshan Hospital, Wuhan, China. Front Pharmacol. 2020;11:600592.
   PubMed Web of Science ®Google Scholar
• Artifoni M, Danic G, Gautier G, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors. J Thromb Thrombolysis. 2020 Jul;50(1):211–216.
   PubMed Web of Science ®Google Scholar
• Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May 01;18(5):1094–1099.
   PubMed Web of Science ®Google Scholar
• Yin S, Huang M, Li D, et al. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis. 2020;1–4.
   Google Scholar
• Smit JM, Lopez Matta JE, Vink R, et al. Coronavirus disease 2019 is associated with catheter-related thrombosis in critically ill patients: a multicenter case-control study. Thromb Res. 2021;200:87–90.
   PubMed Web of Science ®Google Scholar
• Smilowitz NR, Subashchandran V, Yuriditsky E, et al. Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19. Am Heart J. 2020;231:93–95.
   PubMed Web of Science ®Google Scholar
• Stals MAM, Grootenboers MJJH, van Guldener C, et al. Risk of thrombotic complications in influenza versus COVID-19 hospitalized patients. medRxiv. 2020; 2020.12.18.20248265.
   Google Scholar
• Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020 Sep 1;173(5):350–361.
   PubMed Web of Science ®Google Scholar
• Nahum J, Morichau-Beauchant T, Daviaud F, et al. Venous thrombosis among critically Ill patients with coronavirus disease 2019 (COVID-19). JAMA Network Open. 2020 May 1;3(5):e2010478.
   PubMed Web of Science ®Google Scholar
• Minet C, Potton L, Bonadona A, et al. Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. Crit Care (London, England). 2015;19(1):287.
   PubMedGoogle Scholar
• Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020 Aug 01;584(7821):430–436.
   PubMed Web of Science ®Google Scholar
• Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 Jul 01;58(7):1116–1120.
   PubMed Web of Science ®Google Scholar
• Martín-Rojas RM, Pérez-Rus G, Delgado-Pinos VE, et al. COVID-19 coagulopathy: an in-depth analysis of the coagulation system. Eur J Haematol. 2020 Aug 4;105:741–750.
   PubMed Web of Science ®Google Scholar
• Iba T, Levy JH, Levi M, et al. Coagulopathy of coronavirus disease 2019. Crit Care Med. 2020;48(9):1358–1364.
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38; S26–S34.
   Web of Science ®Google Scholar
• Berkman SA, Tapson VF. Methodological issues and controversies in COVID-19 coagulopathy: a tale of two storms. Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620945398.
   Web of Science ®Google Scholar
• Zuo Y, Zuo M, Yalavarthi S, et al. Neutrophil extracellular traps and thrombosis in COVID-19. medRxiv. 2020 May 5.
   Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418.
   PubMed Web of Science ®Google Scholar
• Lazzaroni MG, Piantoni S, Masneri S, et al. Coagulation dysfunction in COVID-19: the interplay between inflammation, viral infection and the coagulation system. Blood Rev. 2020 Aug;100745. DOI:10.1016/j.blre.2020.100745
   PubMed Web of Science ®Google Scholar
• Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Resp Med. 2020 Jun 01;8(6):e46–e47.
   PubMed Web of Science ®Google Scholar
• Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020 Jul 01;26(7):1017–1032.
   PubMed Web of Science ®Google Scholar
• Middleton EA, He XY, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020 Sep 3;136(10):1169–1179.
   PubMed Web of Science ®Google Scholar
• Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation. Respiration. 2017;93(3):212–225.
   PubMed Web of Science ®Google Scholar
• Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020 Jul 01;506:145–148.
   PubMed Web of Science ®Google Scholar
• Qu R, Ling Y, Zhang Y-H-Z, et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol. 2020;92(9):1533–1541.
   PubMed Web of Science ®Google Scholar
• Amgalan A, Othman M. Hemostatic laboratory derangements in COVID-19 with a focus on platelet count. Platelets. 2020 Aug 17;31(6):740–745.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020 Apr 23;382(17):e38.
   PubMed Web of Science ®Google Scholar
• Hasan Ali O, Bomze D, Risch L, et al. Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies. Clin Infect Dis. 2020;ciaa1496. doi:10.1093/cid/ciaa1496
   PubMedGoogle Scholar
• Devreese KMJ, Linskens EA, Benoit D, et al. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost. 2020 Jul 3;18:2191–2201.
   Web of Science ®Google Scholar
• Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res. 2020 Aug;192:113–115.
   PubMed Web of Science ®Google Scholar
• Borghi MO, Beltagy A, Garrafa E, et al. Anti-phospholipid antibodies in COVID-19 are different from those detectable in the anti-phospholipid syndrome. Front Immunol. 2020;11:584241.
   PubMed Web of Science ®Google Scholar
• Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Sem Arthritis Rheum. 2002 Feb 01;31(4):256–263.
   PubMed Web of Science ®Google Scholar
• Harzallah I, Debliquis A, Drénou B. Frequency of lupus anticoagulant in Covid-19 patients. J Thromb Haemost. 2020 May 29.
   Web of Science ®Google Scholar
• Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with covid-19. N Engl J Med. 2020 Jul 16;383(3):288–290.
   PubMed Web of Science ®Google Scholar
• Reyes Gil M, Barouqa M, Szymanski J, et al. Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19). JAMA Network Open. 2020 Aug 3;3(8):e2017539.
   PubMed Web of Science ®Google Scholar
• Siguret V, Voicu S, Neuwirth M, et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients? Thromb Res. 2020 Jul 8;195:74–76.
   PubMed Web of Science ®Google Scholar
• Schouwers SME, Delanghe JR, Devreese KMJ. Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res. 2010 Jan 01;125(1):102–104.
   PubMed Web of Science ®Google Scholar
• Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009 Oct 01;7(10):1737–1740.
   PubMed Web of Science ®Google Scholar
• Huisman MV, Barco S, Cannegieter SC, et al. Pulmonary embolism. Nat Rev Dis Primers. 2018 May 17;4(1):18028.
   PubMedGoogle Scholar
• van der Hulle T, Cheung WY, Kooij S, et al. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017 Jul 15;390(10091):289–297.
   PubMed Web of Science ®Google Scholar
• van der Pol LM, Tromeur C, Bistervels IM, et al. Pregnancy-adapted YEARS algorithm for diagnosis of suspected pulmonary embolism. N Engl J Med. 2019 Mar 21;380(12):1139–1149.
   PubMed Web of Science ®Google Scholar
• Kearon C, de Wit K, Parpia S, et al. Diagnosis of pulmonary embolism with d-dimer adjusted to clinical probability. N Engl J Med. 2019 Nov 28;381(22):2125–2134.
   PubMed Web of Science ®Google Scholar
• Zhang L, Feng X, Zhang D, et al. Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation. 2020 Jul 14;142(2):114–128.
   PubMed Web of Science ®Google Scholar
• Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis. EClinicalMedicine. 2020;29:29.
   Google Scholar
• Klok FA, van der Hulle T, den Exter PL, et al. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev. 2014 Nov 01;28(6):221–226.
   PubMed Web of Science ®Google Scholar
• Rabinovich A, Kahn SR. How I treat the postthrombotic syndrome. Blood. 2018;131(20):2215–2222.
   PubMed Web of Science ®Google Scholar
• Kahn SR, Ducruet T, Lamping DL, et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med. 2005;165(10):1173–1178.
   PubMedGoogle Scholar
• Kahn SR, Akaberi A, Granton JT, et al. Quality of life, dyspnea, and functional exercise capacity following a first episode of pulmonary embolism: results of the ELOPE cohort study. Am J Med. 2017 Aug 01;130(8):990.e9-990.e21.
   PubMed Web of Science ®Google Scholar
• Akaberi A, Klok FA, Cohn DM, et al. Determining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolism-specific quality of life. J Thromb Haemost. 2018;16(12):2454–2461.
   PubMed Web of Science ®Google Scholar
• Grosse C, Grosse A, Salzer HJF, et al. Analysis of cardiopulmonary findings in COVID-19 fatalities: high incidence of pulmonary artery thrombi and acute suppurative bronchopneumonia. Cardiovasc Pathol. 2020 Nov-Dec;49:107263.
   PubMed Web of Science ®Google Scholar
• Hunter R, Lewis S, Noble S, et al. Post-thrombotic panic syndrome”: a thematic analysis of the experience of venous thromboembolism. Brit J Health Psychol. 2017;22(1):8–25.
   PubMed Web of Science ®Google Scholar
• Sista AK, Klok FA. Late outcomes of pulmonary embolism: the post-PE syndrome. Thromb Res. 2018 Apr 01;164:157–162.
   PubMed Web of Science ®Google Scholar
• Chuang LH, van Hout B, Cohen AT, et al. Deep-vein thrombosis in Europe — burden of illness in relationship to healthcare resource utilization and return to work. Thromb Res. 2018 Oct 01;170:165–174.
   PubMed Web of Science ®Google Scholar
• Hunter R, Noble S, Lewis S, et al. Long-term psychosocial impact of venous thromboembolism: a qualitative study in the community. BMJ Open. 2019;9(2):e024805.
   PubMed Web of Science ®Google Scholar
• Tavoly M, Wik HS, Sirnes P-A, et al. The impact of post-pulmonary embolism syndrome and its possible determinants. Thromb Res. 2018 Nov 01;171:84–91.
   PubMed Web of Science ®Google Scholar
• Dhawan RT, Gopalan D, Howard L, et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Resp Med. 2021;9(1):107–116.
   Web of Science ®Google Scholar
• Klok FA, Couturaud F, Delcroix M, et al. Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Eur Resp J. 2020;55(6):2000189.
   PubMed Web of Science ®Google Scholar
• Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Resp J. 2017;49(2):1601792.
   PubMed Web of Science ®Google Scholar
• Ende-Verhaar YM, van den Hout WB, Bogaard HJ, et al. Healthcare utilization in chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J Thromb Haemost. 2018;16(11):2168–2174.
   PubMed Web of Science ®Google Scholar
• Klok FA, Barco S, Konstantinides SV, et al. Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry. Eur Resp J. 2018;52(6):1801687.
   PubMed Web of Science ®Google Scholar
• Boon GJAM, Bogaard HJ, Klok FA. Essential aspects of the follow-up after acute pulmonary embolism: an illustrated review. Res Pract Thromb Haemost. 2020;4(6):958–968.
   PubMed Web of Science ®Google Scholar
• Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): the Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). EurHeart J. 2019;41(4):543–603.
   Google Scholar
• Boon GJAM, Barco S, Bertoletti L, et al. Measuring functional limitations after venous thromboembolism: optimization of the Post-VTE Functional Status (PVFS) Scale. Thromb Res. 2020 Jun 01;190:45–51.
   PubMed Web of Science ®Google Scholar
• Klok FA, Boon GJAM, Barco S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Resp J. 2020;56(1):2001494.
   PubMed Web of Science ®Google Scholar
• Ende-Verhaar YM, Meijboom LJ, Kroft LJM, et al. Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. J Heart Lung Transplant. 2019 Jul 01;38(7):731–738.
   PubMed Web of Science ®Google Scholar
• Guérin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost. 2014;112(3):598–605.
   PubMed Web of Science ®Google Scholar
• Sivaloganathan H, Ladikou EE, Chevassut T. COVID-19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematol. 2020 Jun 25; 190. DOI:10.1111/bjh.16968.
   PubMed Web of Science ®Google Scholar
• Tremblay D, van Gerwen M, Alsen M, et al. Impact of anticoagulation prior to COVID-19 infection: a propensity score–matched cohort study. Blood. 2020;136(1):144–147.
   PubMed Web of Science ®Google Scholar
• Russo V, Di Maio M, Attena E, et al. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: a multicenter observational study. Pharmacol Res. 2020 Sept 01;159:104965.
   PubMed Web of Science ®Google Scholar
• Rossi R, Coppi F, Talarico M, et al. Protective role of chronic treatment with direct oral anticoagulants in elderly patients affected by interstitial pneumonia in COVID-19 era. Eur J Intern Med. 2020 Jul 01;77:158–160.
   PubMed Web of Science ®Google Scholar
• Donze J, Rodondi N, Waeber G, et al. Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med. 2012 Nov;125(11):1095–1102.
   PubMed Web of Science ®Google Scholar
• Piovella C, Dalla Valle F, Trujillo-Santos J, et al. Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry. Intern Emerg Med. 2014 Dec;9(8):847–852.
   PubMed Web of Science ®Google Scholar
• Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels’ striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: the Cremona experience. J Thromb Haemost. 2020 Jun;18(6):1320–1323.
   PubMed Web of Science ®Google Scholar
• Liverpool Drug Interactions Group (University of Liverpool). COVID-19 drug interactions. cited 2020 Dec 15. Available at: https://www.covid19-druginteractions.org/checker
   Google Scholar
• Paolisso P, Bergamaschi L, D’Angelo EC, et al. Preliminary experience with low molecular weight heparin strategy in COVID-19 patients. Front Pharmacol. 2020;11:1124.
   PubMed Web of Science ®Google Scholar
• Atallah B, Sadik ZG, Salem N, et al. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients. Anaesthesia. 2020 Oct 12;76:327–335.
   PubMed Web of Science ®Google Scholar
• Jimenez-Guiu X, Huici-Sánchez M, Romera-Villegas A, et al. Deep vein thrombosis in non-critically ill patients with coronavirus disease 2019 pneumonia: deep vein thrombosis in non-intensive care unit patients. J Vasc Surg Venous Lymphat Disord. 2020 Sep 7. DOI:10.1016/j.jvsv.2020.08.028.
   Google Scholar
• Longhitano Y, Racca F, Zanza C, et al. Venous thrombo-embolism in hospitalized SARS-CoV-2 patients treated with three different anticoagulation protocols: prospective observational study. Biology (Basel). 2020 Sep 24;9(10):310.
   Google Scholar
• Piagnerelli M, Cauchie P, Vancutsem M, et al. Thromboprophylaxis in critically Ill coronavirus disease 2019 patients. Crit Care Explor. 2020 Aug;2(8):e0177.
   PubMedGoogle Scholar
• Eck RJ, Bult W, Wetterslev J, et al. Intermediate dose low-molecular-weight heparin for thrombosis prophylaxis: systematic review with meta-analysis and trial sequential analysis. Sem Thromb Hemost. 2019;45(8):810–824.
   PubMed Web of Science ®Google Scholar
• Mattioli M, Benfaremo D, Mancini M, et al. Safety of intermediate dose of low molecular weight heparin in COVID-19 patients. J Thromb Thrombolysis. 2020 Aug 13;51(2):286–292.
   Web of Science ®Google Scholar
• Pesavento R, Ceccato D, Pasquetto G, et al. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience. J Thromb Haemost. 2020 Oct 01;18(10):2629–2635.
   PubMed Web of Science ®Google Scholar
• Martinelli I, Ciavarella A, Abbattista M, et al. Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Intern Emerg Med. 2021;16:1–7.
   PubMed Web of Science ®Google Scholar
• MacDougall K, Spyropoulos AC. New paradigms of extended thromboprophylaxis in medically Ill patients. J Clin Med. 2020;9(4):1002.
   Web of Science ®Google Scholar
• Patell R, Bogue T, Koshy A, et al. Postdischarge thrombosis and hemorrhage in patients with COVID-19. Blood. 2020 Sep 10;136(11):1342–1346.
   PubMed Web of Science ®Google Scholar
• Roberts LN, Whyte MB, Georgiou L, et al. Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood. 2020 Sep 10;136(11):1347–1350.
   PubMed Web of Science ®Google Scholar
• Anderson DR, Kahn SR, Rodger MA, et al. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA. 2007 Dec 19;298(23):2743–2753.
   PubMed Web of Science ®Google Scholar
• Qanadli SD, Gudmundsson L, Rotzinger DC. Catheter-directed thrombolysis in COVID-19 pneumonia with acute PE: thinking beyond the guidelines. Thromb Res. 2020 Aug;192:9–11.
   PubMed Web of Science ®Google Scholar
• Barrett CD, Moore HB, Yaffe MB, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19: a comment. J Thromb Haemost. 2020 Aug;18(8):2060–2063.
   PubMed Web of Science ®Google Scholar
• van der Hulle T, Kooiman J, den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320–328.
   PubMed Web of Science ®Google Scholar
• Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020 Jun 4;135(23):2033–2040.
   PubMed Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Murthy S, Diaz JV, The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341.
   PubMed Web of Science ®Google Scholar
• Radermecker C, Detrembleur N, Guiot J, et al. Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19. J Exp Med. 2020 Dec 7;217(12). DOI:10.1084/jem.20201012.
   PubMed Web of Science ®Google Scholar
• Tomar B, Anders HJ, Desai J, et al. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19. Cells. 2020 Jun 2;9(6):1383.
   PubMed Web of Science ®Google Scholar
• Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19-related systemic thrombosis? Circulation. 2020 Jun 2;141(22):1739–1741.
   PubMed Web of Science ®Google Scholar
• Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – preliminary report. medRxiv. 2021; 2021.01.07.21249390.
   PubMedGoogle Scholar
• Di Nisio M, Potere N, Candeloro M, et al. Interleukin-6 receptor blockade with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. Eur J Intern Med. 2021 Jan 01;83:34–38.
   PubMed Web of Science ®Google Scholar
• Mughal MS, Kaur I, Kakadia M, et al. Is there any additional benefit of multiple doses of tocilizumab in COVID-19 patients? Cureus. 2020;12(12):e12214–e12214.
   PubMed Web of Science ®Google Scholar
• Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ (Clin Res Ed). 2021;372:n84–n84.
   PubMed Web of Science ®Google Scholar
• Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020 Jun;76:43–49.
   PubMed Web of Science ®Google Scholar